Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Palantir rose after earnings blew past Wall Street estimates, while shares of Vertex Pharmaceuticals and Hims & Hers ...

Vertex Pharmaceuticals stock was among the worst performer in the S&P 500 index early Tuesday after the drugmaker said it ...

Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...

Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic ...

The experimental drug is similar to the Boston-based company’s recently approved pill Journavx but could potentially be given ...

Vertex Pharmaceuticals Inc. shares fell 15% after an experimental pain drug failed to benefit patients after surgery and US ...

Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...

The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic ...

The outcome of the study was just one setback reported by Vertex as it updated investors on its second-quarter results, ...